ArticleFrontiers in cardiovascular medicine2023
Comparative outcomes of two competitive devices for retrograde closure of perimembranous ventricular septal defects.
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Efficacy and Safety of Transarterial Retrograde Approach in Ventricular Septal Defect Closure: A Systematic Review and Meta-Analysis.Anatolian journal of cardiology · 2025Pooled it
- Comparison of KONAR-multifunctional occluder and Amplatzer occluders in transcatheter closure of patent arterial ducts and ventricular septal defects.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Percutaneous closure of native and residual ventricular septal defects using a diverse range of occluder devices: a single-centre experience.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Long-Term Outcomes Following Transcatheter Closure of Small Perimembranous Ventricular Septal Defects.Pediatric cardiology · 2026Article
- Transcatheter Closure of Ventricular Septal Defects after Upfront Transvenous Antegrade Cannulation from the Right Ventricle.Pediatric cardiology · 2026Article
- Optimized retrograde approach and device selection with Konar-MF™ for pediatric transcatheter ventricular septal defect closure.Turk gogus kalp damar cerrahisi dergisi · 2025Article
- Hybrid approach: a prospective option for treating congenital heart defects in pediatric patients.Frontiers in cardiovascular medicine · 2025Review
- Early experience with transcatheter ventricular septal defects closure with the KONAR-MF multifunctional occluder.Frontiers in pediatrics · 2025Article
- Short-term outcomes of transcatheter perimembranous ventricular septal defect closure using the konar-multifunctional occluder: the Taiwanese experience.Frontiers in cardiovascular medicine · 2025Article
- Transcatheter closure of perimembranous ventricular septal defects in elderly patients and risk factors of postoperative arrhythmias.Frontiers in cardiovascular medicine · 2025Article
- Retrograde transarterial closure of small aneurysmal perimembranous ventricular septal defects using the amplatzer duct occluder II: a single-center mid-term analysis.Frontiers in cardiovascular medicine · 2025Article
- Complete percutaneous repair of Tetralogy of Fallot in adult: a case report.Journal of cardiothoracic surgery · 2024Article
- Transcatheter Closure of Perimembranous Ventricular Septal Defects Including Multifenestrated and Gerbode-Type Defects Using the Lifetech Konar Device.Journal of clinical medicine · 2023Article
- Safety and efficacy of Amplatzer duct occluder II and konar-MF™ VSD occluder in the closure of perimembranous ventricular septal defects in children weighing less than 10 kg.Frontiers in cardiovascular medicine · 2023Article
- Comparison of perventricular and percutaneous ultrasound-guided device closure of perimembranous ventricular septal defects.Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retrograde closure of perimembranous ventricular septal defects (pmVSDs) is a well-established procedure. However, interventionists are still looking for the best closure device. Methods: We performed a single-center retrospective review of 5-year-experience (from July 2015 to July 2020) with retrograde closure of pmVSDs using Amplatzer Results: We identified 77 patients (57.1% males) with a median age of 4.3 years (IQR, 2.2-8.3) and a median weight of 16 kg (IQR, 11.2-24.5). 44 (57.1%) defects (22.7% with deficient SARs) with a median left-side defect diameter of 8.7 mm (IQR, 5.7-10) were closed with ADOIIs. 33 (42.9%) defects (51.5% with deficient SARs) with a median left-side defect diameter of 10.8 mm (IQR, 8.8-13.5) were closed with MFOs. One 7/5 MFO was removed before release and upsized to a 12/10 MFO. Implantation success rate was 100% with ADOII and 90.9% with MFO devices. Two MFOs were snare-recaptured after embolization, and one 9/7 MFO was snare-retrieved for a new onset of grade-2 aortic regurgitation that persisted afterward. Median follow-up was 3.3 years (IQR, 2.1-4.2) for ADOII and 2.3 years (IQR, 1.7-2.5) for MFO. No permanent heart block or death occurred. Freedom from left ventricular dilation was 94.62% at 36 months of follow-up. Freedom from residual shunt was 90.62% for MFO and 89.61% for ADOII at 24 months of follow-up. One 2.6-year-old patient with baseline mild aortic valve prolapse and trivial aortic regurgitation developed a grade-2 aortic regurgitation after 9/7 MFO implantation. He was treated surgically after two years without device extraction. One new grade-2 asymptomatic tricuspid regurgitation persisted at the last follow-up in the ADOII group. Conclusions: ADOII and MFO are complementary devices for effective retrograde closure of pmVSDs in children, including defects with absent or deficient SAR. ADOII is limited to smaller defects but offers a lower profile and a flexible left-side disk for better maneuverability over the aortic valve during retrograde implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.